

Neville F Hacker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3087270/publications.pdf>

Version: 2024-02-01

145
papers

8,392
citations

47006

47
h-index

48315

88
g-index

151
all docs

151
docs citations

151
times ranked

8236
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	9
2	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
3	Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis. <i>Gynecologic Oncology</i> , 2021, 160, 128-133.	1.4	10
4	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , 2021, 253, 41-54.	4.5	54
5	Two case studies of cardiac arrest occurring in medically fit patients undergoing radical hysterectomy for cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100823.	0.6	0
6	Medial Inguino-Femoral Lymphadenectomy for Vulvar Cancer: An Approach to Decrease Lymphedema without Compromising Survival. <i>Cancers</i> , 2021, 13, 5806.	3.7	0
7	The Prognostic Role of the Surgical Margins in Squamous Vulvar Cancer: A Retrospective Australian Study. <i>Cancers</i> , 2020, 12, 3375.	3.7	11
8	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1748-1756.	2.5	24
9	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 63.	5.0	8
10	The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	17
11	Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 695-704.	2.5	5
12	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	12.8	110
13	Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers. <i>Cancer Management and Research</i> , 2018, Volume 10, 4709-4718.	1.9	7
14	Response to Re: "Neoadjuvant chemotherapy for advanced ovarian cancer. Who really benefits?". <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2018, 58, E26-E27.	1.0	0
15	Vulvar Cancer. , 2018, , 125-133.		0
16	Improving attendance to genetic counselling services for gynaecological oncology patients. <i>Gynecologic Oncology Research and Practice</i> , 2018, 5, 2.	3.6	2
17	ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer. <i>PLoS ONE</i> , 2018, 13, e0195213.	2.5	9
18	Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. <i>Journal of Ovarian Research</i> , 2017, 10, 8.	3.0	21

#	ARTICLE	IF	CITATIONS
19	Preface: Volume 41. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 1-2.	2.8	1
20	Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma. Molecular Oncology, 2017, 11, 1595-1615.	4.6	24
21	Vulvar cancer in high-income countries: Increasing burden of disease. International Journal of Cancer, 2017, 141, 2174-2186.	5.1	75
22	Surgery for advanced epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 71-87.	2.8	32
23	Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 585-587.	1.0	3
24	Sentinel node biopsy in vulvar cancer: A critical appraisal. Asian Journal of Oncology, 2017, 03, 005-011.	0.2	0
25	Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries. Hereditary Cancer in Clinical Practice, 2017, 15, 12.	1.5	4
26	Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget, 2017, 8, 112727-112738.	1.8	39
27	Should MMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?. Journal of Clinical Oncology, 2017, 35, 5563-5563.	1.6	0
28	Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients. PLoS ONE, 2016, 11, e0164230.	2.5	25
29	Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting. International Journal of Gynecological Cancer, 2016, 26, 1062-1069.	2.5	9
30	Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 633-638.	1.0	9
31	Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review. Gynecologic Oncology Research and Practice, 2016, 3, 7.	3.6	16
32	Genetic testing in a gynaecological oncology care in developing countries—knowledge, attitudes and perception of Nepalese clinicians. Gynecologic Oncology Research and Practice, 2016, 3, 12.	3.6	2
33	Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget, 2015, 6, 40310-40326.	1.8	58
34	Changing Trends in Vulvar Cancer Incidence and Mortality Rates in Australia Since 1982. International Journal of Gynecological Cancer, 2015, 25, 1683-1689.	2.5	43
35	Staging for vulvar cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 802-811.	2.8	23
36	Cancer of the vulva. International Journal of Gynecology and Obstetrics, 2015, 131, S76-83.	2.3	43

#	ARTICLE	IF	CITATIONS
37	Cancer of the vagina. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S84-7.	2.3	42
38	Stage <scp>IB</scp>2 adenosquamous cervical cancer diagnosed at 19â€weeks' gestation. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015, 55, 94-97.	1.0	9
39	Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. <i>Cancer Epidemiology</i> , 2015, 39, 600-611.	1.9	13
40	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.	1.8	37
41	The glycosphingolipid P1 is an ovarian cancer-associated carbohydrate antigen involved in migration. <i>British Journal of Cancer</i> , 2014, 111, 1634-1645.	6.4	40
42	Sexuality and body image following treatment for earlyâ€stage vulvar cancer: a qualitative study. <i>Journal of Advanced Nursing</i> , 2014, 70, 1856-1866.	3.3	25
43	Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells. <i>BMC Molecular Biology</i> , 2014, 15, 24.	3.0	13
44	Effects of Access to and Treatment in Specialist Facilities on Survival From Epithelial Ovarian Cancer in Australian Women: A Data Linkage Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1232-1240.	2.5	24
45	ZNF300P1 Encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. <i>Molecular Cancer</i> , 2014, 13, 3.	19.2	33
46	Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. <i>BMC Genomics</i> , 2014, 15, 476.	2.8	65
47	Reliable in vitro studies require appropriate ovarian cancer cell lines. <i>Journal of Ovarian Research</i> , 2014, 7, 60.	3.0	39
48	A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker. <i>International Journal of Molecular Medicine</i> , 2014, 33, 784-794.	4.0	43
49	Quality of Life After Complete Lymphadenectomy for Vulvar Cancer: Do Women Prefer Sentinel Lymph Node Biopsy?. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 813-819.	2.5	39
50	Primary Surgical Management With Tailored Adjuvant Radiation for Stage IB2 Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 765-772.	2.4	10
51	Data Set for Reporting of Endometrial Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 45-65.	1.4	52
52	Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines. <i>PLoS ONE</i> , 2013, 8, e59180.	2.5	185
53	Loss of Secreted Frizzled-Related Protein 4 Correlates with an Aggressive Phenotype and Predicts Poor Outcome in Ovarian Cancer Patients. <i>PLoS ONE</i> , 2012, 7, e31885.	2.5	51
54	FIGO Cancer Report 2012. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S89.	2.3	14

#	ARTICLE	IF	CITATIONS
55	Cancer of the vulva. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S90-6.	2.3	77
56	Cancer of the vagina. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S97-9.	2.3	38
57	Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership. <i>Gynecologic Oncology</i> , 2012, 127, 75-82.	1.4	165
58	TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 273-279.	2.5	20
59	Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. <i>Cancer Letters</i> , 2012, 318, 76-85.	7.2	48
60	Foreword. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 291-292.	2.8	0
61	Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 124, 582-588.	1.4	91
62	No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. <i>Gynecologic Oncology</i> , 2011, 121, 487-491.	1.4	151
63	Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies. <i>Glycoconjugate Journal</i> , 2011, 28, 507-517.	2.7	38
64	MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. <i>BMC Cancer</i> , 2010, 10, 497.	2.6	49
65	Revised FIGO staging for carcinoma of the vulva. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 105, 105-106.	2.3	104
66	Outcome and Patterns of Recurrence for International Federation of Gynecology and Obstetrics (FIGO) Stages I and II Squamous Cell Vulvar Cancer. <i>Obstetrics and Gynecology</i> , 2009, 113, 895-901.	2.4	85
67	Reasons for Improved Survival From Ovarian Cancer in New South Wales, Australia, Between 1980 and 2003. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 591-599.	2.5	16
68	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. <i>British Journal of Cancer</i> , 2008, 98, 1085-1093.	6.4	56
69	Triage of ovarian masses. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 322-328.	1.0	28
70	DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. <i>Gynecologic Oncology</i> , 2008, 109, 129-139.	1.4	175
71	Epigenetic Markers of Ovarian Cancer. , 2008, 622, 35-51.		13
72	Low meprin Å expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. <i>Journal of Clinical Pathology</i> , 2007, 60, 622-626.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Three cases of endometrial cancer associated with "bioidentical" hormone replacement therapy. Medical Journal of Australia, 2007, 187, 244-245.	1.7	40
74	Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecologic Oncology, 2007, 104, 406-410.	1.4	99
75	Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecologic Oncology, 2007, 106, 44-51.	1.4	33
76	Pathologic Audit of 164 Consecutive Cases of Vulvar Intraepithelial Neoplasia. International Journal of Gynecological Pathology, 2006, 25, 176-181.	1.4	49
77	A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 904-913.	6.4	102
78	Presenting symptoms of epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 211-214.	1.0	43
79	Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA. Gynecologic Oncology, 2005, 99, 153-159.	1.4	227
80	RESPONSE: Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial. Journal of the National Cancer Institute, 2005, 97, 1621-1622.	6.3	3
81	Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial. Journal of the National Cancer Institute, 2005, 97, 560-566.	6.3	434
82	In vitro fertilization surrogate pregnancy in a patient who underwent radical hysterectomy followed by ovarian transposition, lower abdominal wall radiotherapy, and chemotherapy. Fertility and Sterility, 2005, 83, 1547.e7-1547.e9.	1.0	55
83	Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer. Clinical Cancer Research, 2004, 10, 4427-4436.	7.0	189
84	Simultaneous Suppression of Epidermal Growth Factor Receptor and c-erbB-2 Reverses Aneuploidy and Malignant Phenotype of a Human Ovarian Carcinoma Cell Line. Cancer Research, 2004, 64, 789-794.	0.9	29
85	Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer. Clinical Cancer Research, 2004, 10, 5168-5177.	7.0	136
86	Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Research, 2004, 64, 5882-5890.	0.9	884
87	Treatment of recurrent ovarian cancer. Chang Gung Medical Journal, 2004, 27, 570-7.	0.7	4
88	Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases. Gynecologic Oncology, 2003, 89, 9-15.	1.4	9
89	Microinvasive squamous cell carcinoma of the cervix: immunohistochemically detected prognostic factors in a case with poor clinical outcome. Gynecologic Oncology, 2003, 90, 443-445.	1.4	5
90	EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene, 2003, 22, 5070-5081.	5.9	95

#	ARTICLE	IF	CITATIONS
91	The classification, diagnosis and management of endometrial hyperplasia. <i>Reviews in Gynaecological Practice</i> , 2003, 3, 89-97.	0.1	7
92	Secondary Cytoreduction Surgery for Recurrent Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2002, 100, 1360.	2.4	0
93	Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. <i>Obstetrics and Gynecology</i> , 2002, 99, 1008-1013.	2.4	115
94	CONTEMPORARY MANAGEMENT OF PRIMARY CARCINOMA OF THE VULVA. <i>Surgical Clinics of North America</i> , 2001, 81, 799-813.	1.5	15
95	Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. <i>Cancer</i> , 2001, 91, 1437-1443.	4.1	83
96	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. <i>Cancer</i> , 2001, 92, 2837-2844.	4.1	94
97	High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2001, 129, 23-29.	1.0	35
98	Gastrointestinal problems in patients with advanced gynaecological malignancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 253-263.	2.8	2
99	Care of the patient close to death. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 333-340.	2.8	1
100	Optimal management of endometrial hyperplasia. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 393-405.	2.8	46
101	Epidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma Cells. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1375-1384.	6.3	135
102	Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. <i>Cancer</i> , 2001, 91, 1437-1443.	4.1	3
103	Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. <i>Cancer</i> , 2000, 89, 391-398.	4.1	203
104	Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. <i>International Journal of Cancer</i> , 2000, 88, 566-574.	5.1	53
105	Current management of epithelial ovarian carcinoma: A review. <i>Journal of Surgical Oncology</i> , 2000, 19, 11-19.	1.4	70
106	Laparoscopic Port-Site Recurrence Following Surgery for a Stage IB Squamous Cell Carcinoma of the Cervix with Negative Lymph Nodes. <i>Gynecologic Oncology</i> , 2000, 79, 324-326.	1.4	36
107	Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. <i>Cancer</i> , 2000, 89, 391-398.	4.1	112
108	Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. , 2000, 88, 566.		1

#	ARTICLE	IF	CITATIONS
109	Interleukin-6 (IL-6) Does Not Change the Expression of Bcl-2 Protein in the Prevention of Cisplatin-Induced Apoptosis in Ovarian Cancer Cell Lines. <i>Journal of Obstetrics and Gynaecology Research</i> , 1999, 25, 23-27.	1.3	3
110	Vaginal Reconstruction in the Fibrotic Pelvis. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1999, 39, 448-453.	1.0	13
111	Protein kinase A- β subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. <i>Oncogene</i> , 1999, 18, 4999-5004.	5.9	33
112	Effects of interleukin-6 (IL-6) on chemotherapy-induced apoptosis in human ovarian cancer cell lines. <i>International Journal of Clinical Oncology</i> , 1999, 4, 84-89.	2.2	1
113	Adjuvant small field pelvic radiation for patients with high risk, Stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. , 1999, 86, 2059-2065.		30
114	Adjuvant small field pelvic radiation for patients with high risk, Stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. <i>Cancer</i> , 1999, 86, 2059-2065.	4.1	6
115	Radical resection of vulvar malignancies: a paradigm shift in surgical approaches. <i>Current Opinion in Obstetrics and Gynecology</i> , 1999, 11, 61-64.	2.0	17
116	p53 Protein Overexpression: A Strong Prognostic Factor in Uterine Papillary Serous Carcinoma. <i>Gynecologic Oncology</i> , 1998, 71, 59-63.	1.4	29
117	Influence of Postoperative Treatment on Survival in Patients with Uterine Papillary Serous Carcinoma. <i>Gynecologic Oncology</i> , 1998, 71, 344-347.	1.4	44
118	Organization of gynecological cancer care: a time for change. <i>International Journal of Gynecological Cancer</i> , 1998, 8, 1-5.	2.5	3
119	Vulvar intraepithelial neoplasia and carcinoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1998, 17, 205-212.	1.6	5
120	Prognostic factors in squamous cell cancer of the vulva and the implications for treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 1996, 8, 3-7.	2.0	10
121	Expression of cell regulatory proteins in ovarian borderline tumors. , 1996, 77, 2092-2098.		25
122	Uterine papillary serous carcinoma. A clinical study. <i>Cancer</i> , 1995, 75, 2239-2243.	4.1	86
123	Reproductive and other factors and risk of epithelial ovarian cancer: An australian case-control study. <i>International Journal of Cancer</i> , 1995, 62, 678-684.	5.1	224
124	Endometrial cancer in premenopausal women 45 years and younger. <i>Obstetrics and Gynecology</i> , 1995, 85, 504-508.	2.4	166
125	Surgical Therapy of Vulvar Cancer in Pregnancy. <i>Gynecologic Oncology</i> , 1995, 56, 312-315.	1.4	25
126	Systematic Pelvic and Paraaortic Lymphadenectomy for Advanced Ovarian Cancer—Therapeutic Advance or Surgical Folly?. <i>Gynecologic Oncology</i> , 1995, 56, 325-327.	1.4	34

#	ARTICLE	IF	CITATIONS
127	A Combined Abdominoperineal Approach for the Resection of a Large Giant Cell Tumor of the Sacrum. <i>Gynecologic Oncology</i> , 1995, 57, 113-116.	1.4	4
128	Update on vulvar carcinoma. <i>Cancer Treatment and Research</i> , 1994, 70, 101-119.	0.5	6
129	The case against aspirating ovarian cysts. <i>Cancer</i> , 1993, 72, 828-831.	4.1	96
130	Conservative management of early vulvar cancer. <i>Cancer</i> , 1993, 71, 1673-1677.	4.1	126
131	The Papanicolaou smear histories of 237 patients with cervical cancer. <i>Medical Journal of Australia</i> , 1992, 157, 14-16.	1.7	20
132	Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. <i>Gynecologic Oncology</i> , 1991, 42, 197-201.	1.4	91
133	Surgery for Gynaecological Cancer: Results Since the Introduction of Radical Operations. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1990, 30, 24-28.	1.0	5
134	Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 1990, 38, 309-314.	1.4	396
135	Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 1990, 37, 9-16.	1.4	51
136	Sexual Functioning After Treatment for Endometrial Cancer. <i>Journal of Psychosocial Oncology</i> , 1987, 5, 47-61.	1.2	128
137	Positive groin lymph nodes in superficial squamous cell vulvar cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1987, 156, 1159-1164.	1.3	156
138	Rhabdomyosarcoma of the uterine cervix. <i>Sarcoma botryoides</i> . <i>Cancer</i> , 1987, 60, 1552-1560.	4.1	79
139	Cytoreductive Surgery in Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 1986, 67, 783-788.	2.4	134
140	Correlates of Delay in Seeking Treatment for Endometrial Cancer. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 1986, 5, 245-252.	2.1	19
141	Preoperative radiation therapy for locally advanced vulvar cancer. <i>Cancer</i> , 1984, 54, 2056-2061.	4.1	137
142	Superficially invasive vulvar cancer with nodal metastases. <i>Gynecologic Oncology</i> , 1983, 15, 65-77.	1.4	74
143	Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 1982, 13, 87-92.	1.4	41
144	Postcoital Posthysterectomy Vaginal Vault Disruption With Haemorrhagic Shock. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1980, 20, 182-184.	1.0	2

#	ARTICLE	IF	CITATIONS
145	The Management of Microinvasive Carcinoma of the Cervix. , 0, , 531-539.		0